Filing Flows › PTC Therapeutics (PTCT) › Q2 2026 › vs Q1 2026
PTC Therapeutics (PTCT) Q2 2026 vs Q1 2026 (quarter over quarter)
PTC Therapeutics's revenue rose $88.0M (+32%) from $273M in Q1 2026 to $361M in Q2 2026. The biggest changes: Collaboration and license revenue +$50.5M (354×); Royalty revenue +$24.3M (+52%); Net product revenue +$13.2M (+6%). Operating margin 41.3% against 16.5% (+24.8 pts).
PTC Therapeutics, Q2 2026: revenue $361M (+102% year over year), operating margin 41.3%, net earnings $83.5M, operating cash flow $129M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Operating margin | 41.3% | 16.5% | +24.8 pts |
| Net margin | 23.2% | -1.0% | +24.2 pts |
| Free cash flow margin | 35.2% | -22.1% | +57.3 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Sephience | $151M | $125M | $26.8M | +21% |
| Translarna | $42.2M | $59.0M | −$16.8M | -28% |
| Emflaza | $24.6M | $21.5M | $3.2M | +15% |
| Upstaza/Kebilidi | $11.2M | $9.6M | $1.6M | +16% |
| All other products | $9.5M | $11.0M | −$1.5M | -13% |
| Net product revenue | $239M | $226M | $13.2M | +6% |
| Royalty revenue | $71.1M | $46.8M | $24.3M | +52% |
| Collaboration and license revenue | $50.6M | $143K | $50.5M | 354× |
| Revenue | $361M | $273M | $88.0M | +32% |
| Operating profit | $149M | $45.0M | $104M | +231% |
| Costs & expenses | $212M | $228M | −$16.1M | -7% |
| Pre-tax earnings | $97.5M | −$2.5M | $100M | — |
| Other expense, net | $51.4M | $47.4M | $4.0M | +8% |
| Research & development | $99.2M | $101M | −$1.7M | -2% |
| SG&A | $80.6M | $86.2M | −$5.6M | -6% |
| Other operating costs | $31.8M | $40.5M | −$8.8M | -22% |
| Net earnings | $83.5M | −$2.8M | $86.3M | — |
| Income tax | $14.0M | $347K | $13.7M | 40× |
| Depreciation & amortization | $15.9M | $15.4M | $461K | +3% |
| Share-based compensation | $23.3M | $23.4M | −$130K | -0.6% |
| Working capital & other | $6.5M | −$95.1M | $102M | — |
| Operating cash flow | $129M | −$59.0M | $188M | — |
| Free cash flow (OCF − capex) | $127M | −$60.2M | $187M | — |
| Capital expenditures | $2.2M | $1.2M | $995K | +83% |
Questions
How much did PTC Therapeutics's revenue grow quarter over quarter in Q2 2026?
PTC Therapeutics's revenue rose $88.0M (+32%) from $273M in Q1 2026 to $361M in Q2 2026.
What drove PTC Therapeutics's revenue change in Q2 2026?
Collaboration and license revenue +$50.5M (354×); Royalty revenue +$24.3M (+52%); Net product revenue +$13.2M (+6%).